Our Common Bond: Medical Innovation

Lots of activity around here yesterday: The New York Times wrote about our new neighbors at CityWay -- the new connection between Lilly and downtown Indianapolis -- while Forbes.com published another column on medical innovation by our Chairman and CEO, John Lechleiter.

But I would be remiss if I didn't spend at least a few paragraphs talking about TransCelerate BioPharma, Inc., a new non-profit organization that will orchestrate 10 companies (including Lilly) and dozens of scientists as they pool their brainpower, their know-how, and their money to find solutions to common barriers in the pursuit of innovative medical treatments for patients.

Lilly is joining Abbott, Astra-Zeneca, Boehringer Ingelheim, Bristol Myers-Squibb, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech, and Sanofi in this unique industry wide effort.

As Jeff Kasher, vice president of Lilly's Development Center of Excellence, told The Indianapolis Star: "I don't want to overpromise, but I'm very optimistic we are going to see solutions come out (of this) to enable more rapid development of innovative medicines."

That's a big-time need right now. With the incidence of diabetes and cancer continuing to increase -- and the growth of Alzheimer's disease a medical and financial tsunami waiting to happen -- finding solutions to barriers is an important part of the mix. The first project for TransCelerate: finding better ways to perform clinical trials. 

Lilly has committed to three years to the project. You can read more on IndyStar.com